Treatment and outcomes of dogs with hepatocutaneous syndrome or hepatocutaneous‐associated hepatopathy

Abstract

Abstract Background Superficial necrolytic dermatitis (SND) in dogs is a rare disorder most commonly associated with hepatocutaneous syndrome. Although often reported as fatal, sporadically reported long‐term remissions might be more common than previously believed and linked to treatment regimens. Hypothesis/Objectives Evaluate treatments and associated outcomes in dogs with hepatocutaneous‐associated hepatopathy (HCH) with or without SND, designated collectively aminoaciduric canine hypoaminoacidemic hepatopathy syndrome (ACHES). Animals Forty‐one dogs of various breeds and ages diagnosed with ACHES. Methods Retrospective study. Electronic surveys, medical records (2014‐2019), and communication with veterinarians provided data. Three treatment categories were each dichotomized: IV amino acid (IV‐AA) infusions (≥2 vs 1783 days, P = .02) than variably treated dogs (MST, 214 days). Conclusions and Clinical Importance Optimized ACHES management can resolve SND and HCH and confer long‐term survival.

Keywords

• hepatic disease
• internal medicine‐canine
• metabolic disease